Placenta-Targeted Nanoparticles: A New Frontier in Recurrent Pregnancy Loss – Reproduction and Fertility
Reproduction and Fertility shared a post on LinkedIn:
“Day 4 of RaFJC – Placenta-Targeted Nanoparticles: A New Frontier in Recurrent Pregnancy Loss (RPL)
Recurrent pregnancy loss (RPL) (two or more consecutive miscarriages) affects 1–2% of couples worldwide. Up to 50% of cases remain unexplained, with immune maladaptation at the maternal–fetal interface increasingly recognised as a key driver.
Current therapies rely on systemic immunosuppression (corticosteroids, IVIG, TNF inhibitors), which:
- Show inconsistent efficacy
- Carry significant risks
- Are costly and not always accessible
This highlights the urgent need for localised, safer, and cost‑effective therapies.
Mohsen Dashti, Vinnie A., and Mehdi Yousefi propose a placenta‑targeted nanoparticle (NP) system for localized immune cloaking.
Core design:
- PLGA biodegradable matrix
- Lipid‑PEG stealth layer to prolong circulation
- SPIONs for imaging and tracking
- Placental‑homing peptides for site‑specific delivery
Evidence so far:
- Rodent and primate models show placenta‑specific NP delivery is feasible
- NPs can induce anti‑inflammatory cytokines, suppress cytotoxic NK/T cells, and remodel spiral arteries
- Ex vivo human placenta models confirm uptake with minimal fetal exposure
Estimated cost: $0.56–$5.58 per dose, far cheaper than IVIG or biologics. Production is scalable.
In conclusion, placenta‑targeted nanoparticles represent a promising therapy for unexplained RPL, offering localized immune tolerance while avoiding systemic risks.
Read the full article.
Join the discussion in the comments:
- What challenges must be overcome for clinical translation?
- How might localised immune cloaking reshape patient care?
- Which biomarkers should guide future trials?
Explore the Special Collection: Immune Regulation and Inflammatory Mechanisms in Reproductive Health and Disease.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Dec 13, 2025, 03:57Yasmine Candau: I Was Once Only a Patient, Today I Put My Experience at the Service of Others
-
Dec 13, 2025, 03:43Impact of Chromosome Recombination Failures in Human Eggs – Fertility Plus
-
Dec 13, 2025, 03:06Roberto Costillas Perez: Vaginal Microbiota’s Role in Assisted Reproduction Outcomes
-
Dec 13, 2025, 02:43Marieke Ogay։ Antioxidant Status and Magnesium։ Key to Miscarriage Risk?
-
Dec 13, 2025, 02:00Immune Signatures in Early Pregnancy: Predicting Outcomes in ART Patients – Reproduction and Fertility
-
Dec 12, 2025, 15:11Webinar on Fertility Preservation in Cancer Care – ESHRE
-
Dec 12, 2025, 14:59Novel Microfluidics Device Enhances Sperm Selection Success – Fertility and Sterility
-
Dec 12, 2025, 14:55Human Embryo Preimplantation Genetic Testing and Phased Validation – Fertility and Sterility
-
Dec 12, 2025, 14:40Unraveling Immune Mechanisms in Reproductive Health – Reproduction and Fertility